Fig. 1 · Structure

Documents & Downloads

AS-252424

Cat. No. A11099 CAS 900515-16-4

PI3K inhibitor

AS-252424 is a potent inhibitor of PI3K with selectivity for the γ isoform. It inhibits human recombinant PI3Kγ, α, β, and δ with IC50 values of 30, 940, 20,000, and 20,000 nM respectively.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
Casein Kinase 2 (Cell-free assay) 20 nM
PI3Kγ (Cell-free assay) 33 nM
PI3Kα (Cell-free assay) 935 nM

In Vitro Studies

In mouse cardiomyocytes, AS-252424 treatment yielded a lower average intracellular calcium concentration than control. In mouse primary B cells stimulated with αIgM and interleukin-4, AS-252424 had no significant effect on AKT or ERK1/2 phosphorylation compared with diluent control. [1,2]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Inhibitor Perfusion and Intracellular Calcium in Mouse Cardiomyocytes

Cell-based study · HL-1 cell mouse cardiomyocytes; n = 5, each an average of 25 to 40 cells [1]

HL-1 mouse cardiomyocytes were perfused with the inhibitor at 100 nM. At 15 min, average intracellular calcium in cells displaying oscillating and non-oscillating calcium was 111.9 ± 6.0 nM, compared with control 121.8 ± 4.3 nM (P <0.03).

Measured endpoints — not treatment concentrations
EndpointReported resultReference
average [Ca2+]i in cells displaying oscillating and non-oscillating [Ca2+]i[Ca2+]i 100 nM, 15 min: 111.9 ± 6.0 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 nM
Exposure duration
15 minutes after addition of respective inhibitors
Method
perfused
Vehicle
DMSO
Methods and source locations

Compound reported in the paper: AS-252424

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods > Intracellular Ca2+ measurements (S16, S27); Methods > Solutions and chemicals (S40); Figure 4 legend (S92, S97); Table 3 legend (S116); Table 3 (T3.h1, T3.r2)

average [Ca2+]i in cells displaying oscillating and non-oscillating [Ca2+]i: average [Ca2+]i in cells displaying oscillating and non-oscillating [Ca2+]i; comparator: 121.8 ± 4.3 nM — Figure 4 legend (S97); Table 3 (T3.h1, T3.r2)

AKT Phosphorylation in Stimulated Mouse B Cells

Cell-based study · mouse primary B cells [2]

In mouse primary B cells stimulated with αIgM and interleukin-4, AS-252424 at 100 nM, 300 nM, and 1 µM had no significant effect on AKT phosphorylation compared with diluent control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
phosphorylation of AKT at the serine 473 residueReported result 100 nM, 300 nM, and 1 µM; αIgM + IL-4 stimulated mouse B cells: AS-252424 had no significant effect on p-AKT signaling.[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 nM, 300 nM, and 1 µM
Exposure duration
pretreated with inhibitors as indicated for 30 min then activated with 5 µg/mL αIgM + 10 ng/mL interleukin-4 (IL-4) for 1 h before harvest for western blot
Vehicle
0.1% EtOH
Co-treatment
Other interventions in this design: αIgM 5 µg/mL; interleukin-4 (IL-4) 10 ng/mL. Compound effect isolated by the comparison: AS-252424 or its diluent control (0.1% EtOH).
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: AS-252424

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Inhibition of p110δ, but Not p110γ, Reduces p-AKT in Activated Mouse B Cells (S5, S7, S9); Figure 1 legend (S100, S101, S103)

phosphorylation of AKT at the serine 473 residue: phosphorylation of AKT at the serine 473 residue; comparator: diluent control (0.1% EtOH) — Results > Inhibition of p110δ, but Not p110γ, Reduces p-AKT in Activated Mouse B Cells (S5, S9); Figure 1 legend (S100, S103)

ERK Phosphorylation in Stimulated Mouse B Cells

Cell-based study · mouse primary B cells [2]

In mouse primary B cells stimulated with αIgM and interleukin-4, AS-252424 at 100 nM, 300 nM, and 1 µM had no significant effect on ERK1/2 phosphorylation compared with diluent control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
phosphorylation of ERK1/2 on Thr202/Tyr204 residuesReported result 100 nM, 300 nM, and 1 µM; αIgM + IL-4 stimulated mouse B cells; p-ERK1/2: AS-252424 had no significant effect.[2]

Literature-Reported Treatment Conditions

Treatment concentration
100 nM, 300 nM, and 1 µM
Exposure duration
pretreated with inhibitors as indicated for 30 min then activated with 5 µg/mL αIgM + 10 ng/mL interleukin-4 (IL-4) for 1 h before harvest for western blot
Vehicle
0.1% EtOH
Co-treatment
Other interventions in this design: αIgM 5 µg/mL; interleukin-4 (IL-4) 10 ng/mL. Compound effect isolated by the comparison: AS-252424 or its diluent control (0.1% EtOH).
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: AS-252424

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > Inhibition of p110δ, but Not p110γ, Reduces p-AKT in Activated Mouse B Cells (S5, S7, S10); Figure 1 legend (S100, S101, S103)

phosphorylation of ERK1/2 on Thr202/Tyr204 residues: phosphorylation of ERK1/2 on Thr202/Tyr204 residues; comparator: diluent control (0.1% EtOH) — Results > Inhibition of p110δ, but Not p110γ, Reduces p-AKT in Activated Mouse B Cells (S5, S10); Figure 1 legend (S100, S103)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 900515-16-4
Applications PI3K inhibitor
Formula C14H8FNO4S
Molecular Weight 305.3
SMILES
C1=CC(=C(C=C1F)O)C2=CC=C(O2)/C=C\3/C(=O)NC(=O)S3

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 57 mg/mL (186.71 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
4% DMSO+50% PEG 300+5% Tween 80+ddH2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Graves BM, Simerly T, Li C, et al. Phosphoinositide-3-kinase/akt - dependent signaling is required for maintenance of [Ca(2+)](i), I(Ca), and Ca(2+) transients in HL-1 cardiomyocytes. J Biomed Sci (2012). PMID: 22715995 DOI: 10.1186/1423-0127-19-59 Source material
  2. [2] Chiu H, Mallya S, Nguyen P, et al. The Selective Phosphoinoside-3-Kinase p110δ Inhibitor IPI-3063 Potently Suppresses B Cell Survival, Proliferation, and Differentiation. Front Immunol (2017). PMID: 28713374 DOI: 10.3389/fimmu.2017.00747 Source material

Added to your cart

View Cart Checkout
Loading...